-
Mashup Score: 15APCCC 2024: Future Changes in the Setting of mHSPC - 15 hour(s) ago
APCCC 2024 management of mHSPC, future changes in the setting of mHSPC, role for immune checkpoint inhibition in unselected M1 prostate cancer among men starting ADT, CAPItello-281, AMPLITUDE, TALAPRO-3, PSMAddition, CYCLONE-03.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 8APCCC 2024: Management of Frail Patients with mHSPC - 17 hour(s) ago
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Management of Frail Patients with mHSPC, M1 disease, abiraterone, prednisolone, abiraterone plus prednisolone, androgen deprivation therapy (ADT), enzalutamide, apalutamide, darolutamide, LHRH antagonists, androgen receptor pathway inhibitor (ARPI).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 14APCCC 2024: Management of Patients with mHSPC and Early Progression on Combination Therapy - 18 hour(s) ago
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), mHSPC and early progression on combination therapy, androgen deprivation therapy (ADT), abiraterone, enzalutamide, apalutamide, darolutamide, androgen deprivation therapy plus abiraterone, androgen deprivation therapy plus enzalutamide, androgen deprivation therapy plus apalutamide, androgen deprivation therapy plus darolutamide, ENZAMET trial, PSMAfore trial, p53, RB1, PTEN, oligometastatic prostate cancer, VISION trial, LuPSMA, cabazitaxel, LuPSMA versus cabazitaxel, PROfound trial, TAX-327 trial, mitoxantrone, olaparib, TROPIC trial, CARD trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 15APCCC 2024: Genomic Classifiers and Artificial Intelligence as Predictors for Treatment Benefit - 18 hour(s) ago
APCCC 2024 advanced prostate cancer, use of genomic classifiers and artificial intelligence tools as predictors of treatment benefit in prostate cancer patients, prostate cancer mortality, Decipher®.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 12APCCC 2024: Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? - 18 hour(s) ago
APCCC 2024 management of mHSPC, EMA established the Cancer Medicines Forum, androgen deprivation and continuing the ARTA, LIBERTAS study, EMBARK, DE-ESCALATE EORTC 2238 trial, intermittent androgen deprivation.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9APCCC 2024: Update on the IRONMAN Project - 18 hour(s) ago
APCCC 2024 update on the IRONMAN project, IRONMAN Executive Committee, treatment of advanced prostate cancer, Engaging Men in Patient Reported Outcomes, PROfound study, abiraterone, enzalutamide, apalutamide, darolutamide, Movember Foundation.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9APCCC 2024: Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? - 19 hour(s) ago
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Escalation Strategies in Patients with mHSPC, Unfavourable PSA Decline, PSA progression, radiographic progression, clinical progression, CHAARTED data, LATITUDE trial, Titan Trial, STAMPEDE data.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 13APCCC 2024: In Which Patients with Metachronous Low-volume mHSPC Do You Recommend “total Therapy”? - 19 hour(s) ago
APCCC 2024 metastatic hormone-sensitive prostate cancer (mHSPC), metachronous low-volume mHSPC, ‘total therapy’ with metastasis-directed therapy (MDT), ‘Pokemet’ approach,
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 15
APCCC 2024, Advanced Prostate Cancer, radical prostatectomy, pelvic lymph node dissection, cN1 disease, Extended pelvic lymph node dissection, RAVES trial, RADICALS-RT trial, GETUG 17 trial, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), androgen deprivation therapy (ADT).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
How to best manage a fit patient with high-risk localized and locally advanced #ProstateCancer? Surgery as radical local treatment (as part of a multimodality approach). Presented by @Albert0Briganti @MyUniSR. #APCCC24 written coverage by @RKSayyid @UofT > https://t.co/hlG4SNkGFf https://t.co/PsLsfMuUC3
-
-
Mashup Score: 15APCCC 2024: Radiation Therapy Schedules and Fields for High-Risk and Locally Advanced Prostate Cancer - 19 hour(s) ago
APCCC 2024, prostate cancer, Radiation Therapy Schedules for prostate cancer, Locally Advanced Prostate Cancer, GETUG-AFU 18 trial, dose-escalated external beam radiotherapy, ultrahypofractionation, ultrahypofractionation via stereotactic body radiotherapy, Stereotactic Body Radiotherapy (SBRT), SHARP (Stereotactic Body Radiotherapy [SBRT] for High-Risk Localized Carcinoma of the Prostate), ASCENDE-RT (Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy) trial, FLAME (Focal Lesion Ablative Microboost in Prostate Cancer) trial, POP-RT trial, PEACE V- STORM (Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases) trial, metastasis-directed therapy (MDT), OLIGOPELVIS-GETUG P07 trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Future changes in the setting of #mHSPC. Presentation by @AttardLab @ucl. #APCCC24 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/EpOdJRtYqr @APCCC_Lugano https://t.co/mmv56badI5